» Articles » PMID: 18802790

Heterogeneity of Prostate-specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis

Overview
Specialty Oncology
Date 2008 Sep 20
PMID 18802790
Citations 173
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in advanced stage prostate adenocarcinomas. As a novel target for in vivo prognostic and therapeutic approaches, the distribution pattern of PSMA in primary and metastatic tumors is of significant interest. In this study we addressed the cellular distribution and heterogeneity of PSMA expression. Paraffin-embedded sections of 51 patients with primary prostate carcinoma and distant metastases were evaluated. Immunohistochemistry was used to determine the cellular localization, staining intensity and positive cell fraction which were related to tumor type and growth pattern. We demonstrated differences in the intracellular localization of the PSMA immunostaining which seem to be related to the tumor differentiation pattern. A significant number of the primary tumors (7/51) and metastases (6/51) presented with highly heterogeneous PSMA expression and in further 2 primary, and 8 metastatic tumors the staining was in the negative range (<10% positive tumor cells). A direct correlation between histological parameters and PSMA expression could not be demonstrated. Our findings clearly support the feasibility but also direct to potential failures of PSMA-targeted in vivo diagnostic and therapeutic approaches in prostate cancer patients with distant metastasis.

Citing Articles

Optical and MRI-Guided Theranostic Application of Ultrasmall Superparamagnetic Iron Oxide Nanodrug Conjugate for PSMA-Positive Prostate Cancer Therapy.

Surasinghe S, Liatsou I, Novakova Z, Barinka C, Artemov D, Hapuarachchige S ACS Appl Mater Interfaces. 2025; 17(8):11611-11623.

PMID: 39933703 PMC: 11873945. DOI: 10.1021/acsami.4c16009.


The Application of Prostate Specific Membrane Antigen in the Diagnosis and Treatment of Prostate Cancer: Status and Challenge.

Zeng T, Xie Y, Chai K, Sang H Onco Targets Ther. 2024; 17:991-1015.

PMID: 39564453 PMC: 11573878. DOI: 10.2147/OTT.S485869.


Design, preclinical evaluation, and first-in-human PET study of [Ga]Ga-PSFA-01: a PSMA/FAP heterobivalent tracer.

Wang X, Zhang X, Zhang X, Guan L, Gao X, Xu L Eur J Nucl Med Mol Imaging. 2024; 52(3):1166-1176.

PMID: 39520516 DOI: 10.1007/s00259-024-06965-7.


DOTA Conjugate of Bisphosphonate and PSMA-Inhibitor: A Promising Combination for Therapy of Prostate Cancer Related Bone Metastases.

Grus T, Lahnif H, Bausbacher N, Miederer M, Rosch F Front Nucl Med. 2024; 2:892147.

PMID: 39354968 PMC: 11440839. DOI: 10.3389/fnume.2022.892147.


Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis.

Bilgin G, Bilgin C, Orscelik A, Burkett B, Thorpe M, Johnson D Ann Nucl Med. 2024; 38(11):865-876.

PMID: 39287742 DOI: 10.1007/s12149-024-01978-6.


References
1.
Elsasser-Beile U, Wolf P, Gierschner D, Buhler P, Schultze-Seemann W, Wetterauer U . A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate. 2006; 66(13):1359-70. DOI: 10.1002/pros.20367. View

2.
Lopez-Beltran A, Mikuz G, Luque R, Mazzucchelli R, Montironi R . Current practice of Gleason grading of prostate carcinoma. Virchows Arch. 2005; 448(2):111-8. DOI: 10.1007/s00428-005-0102-4. View

3.
Horoszewicz J, Kawinski E, Murphy G . Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987; 7(5B):927-35. View

4.
Sodee D, Sodee A, Bakale G . Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2006; 37(1):17-28. DOI: 10.1053/j.semnuclmed.2006.07.002. View

5.
Ross J, Sheehan C, Fisher H, Kaufman Jr R, Kaur P, Gray K . Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003; 9(17):6357-62. View